Literature DB >> 20165582

Nephrectomy is necessary in the treatment of metastatic renal cell carcinoma.

Tamer Abou Youssif1, Simon Tanguay.   

Abstract

Entities:  

Year:  2010        PMID： 20165582      PMCID： PMC2812002          DOI： 10.5489/cuaj.778

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  10 in total

Review 1.  Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression.

Authors:  Christopher S Ng; Andrew C Novick; Charles S Tannenbaum; Ronald M Bukowski; James H Finke
Journal:  Urology       Date:  2002-01       Impact factor: 2.649

2.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.

Authors:  Ronald J Halbert; Robert A Figlin; Michael B Atkins; Myriam Bernal; Thomas E Hutson; Robert G Uzzo; Ronald M Bukowski; Khuda Dad Khan; Christopher G Wood; Robert W Dubois
Journal:  Cancer       Date:  2006-11-15       Impact factor: 6.860

4.  Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.

Authors:  A Belldegrun; O Shvarts; R A Figlin
Journal:  Cancer J Sci Am       Date:  2000-02

5.  Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells.

Authors:  Daisuke Kudo; Patricia Rayman; Claudine Horton; Martha K Cathcart; Ronald M Bukowski; Mark Thornton; Charles Tannenbaum; James H Finke
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

6.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.

Authors:  Fanny Chagnon; Simon Tanguay; Ozdem Levent Ozdal; Meng Guan; Zeynep Z Ozen; Jean-Sébastien Ripeau; Mario Chevrette; Mostafa M Elhilali; Lu Ann Thompson-Snipes
Journal:  Clin Cancer Res       Date:  2005-02-01       Impact factor: 12.531

8.  Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine.

Authors:  M Gigante; A Blasi; A Loverre; V Mancini; M Battaglia; F P Selvaggi; E Maiorano; A Napoli; G Castellano; W J Storkus; L Gesualdo; E Ranieri
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

9.  Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.

Authors:  Laurent Zini; Umberto Capitanio; Paul Perrotte; Claudio Jeldres; Shahrokh F Shariat; Philippe Arjane; Hugues Widmer; Francesco Montorsi; Jean-Jacques Patard; Pierre I Karakiewicz
Journal:  Urology       Date:  2008-11-28       Impact factor: 2.649

10.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450
  10 in total
  1 in total

1.  An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation.

Authors:  Alberto Carmona Bayonas
Journal:  Cancers (Basel)       Date:  2011-03-02       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.